Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Muscular Dystrophy

  • Author: Twee T Do, MD; Chief Editor: Jeffrey D Thomson, MD  more...
 
Updated: Dec 18, 2015
 

Background

Muscular dystrophy (MD) is a collective group of inherited noninflammatory but progressive muscle disorders without a central or peripheral nerve abnormality. The disease affects the muscles with definite fiber degeneration but without evidence of morphologic aberrations.

The first historical account of MD was reported by Conte and Gioja in 1836.[1] They described two brothers with progressive weakness starting at age 10 years. These boys later developed generalized weakness and hypertrophy of multiple muscle groups, which are now known to be characteristic of the milder Becker MD. At the time, however, many thought that Conte and Gioja described tuberculosis; thus, they did not achieve recognition for their discovery.

In 1852, Meryon[2] reported in vivid details a family with four boys, all of whom were affected by significant muscle changes but had no central nervous system abnormality when examined at necropsy. Meryon subsequently wrote a comprehensive monograph on MD and even went on to suggest a sarcolemmal defect to be at the root of the disorder. He further suspected that the disorder is genetically transmitted through females and affects only males.

Guillaume Duchenne was a French neurologist who was already famous for his application of faradism (the use of electric currents to stimulate muscles and nerves) in the treatment of neurologic disorders when he wrote about his first case of MD.[3] In 1868, he gave a comprehensive account of 13 patients with the disease, which he called "paralysie musculaire pseudo-hypertrophique." Because Duchenne was already held in high esteem for his work in faradism and for his contributions to the understanding of muscle diseases, one of the most severe and classic forms of MD, Duchenne MD, now bears his name.

The advancement of molecular biology techniques illuminates the genetic basis underlying all MD: defects in the genetic code for dystrophin, a 427-kd skeletal muscle protein (Dp427). These defects result in the various manifestations commonly associated with MD, such as weakness and pseudohypertrophy. Dystrophin can also be found in cardiac smooth muscles and in the brain (accounting for the slight mental retardation associated with this disease).[4]

Minor variations notwithstanding, all types of MD have in common progressive muscle weakness that tends to occur in a proximal-to-distal direction, though there are some rare distal myopathies that cause predominantly distal weakness. The decreasing muscle strength in those who are affected may compromise the patient's ambulation potential and, eventually, cardiopulmonary function.

In addition, structural soft-tissue contractures and spinal deformities may develop from poor posturing caused by the progressive muscle weakness and imbalance, all of which can further compromise function and longevity. Equinovarus contractures start as flexible dynamic deformities and advance to rigid contractures. This altered anatomy prevents normal ambulation, proper shoe wear, and transfers (how patients can be picked up to transfer out of their chair).

Once wheelchair-bound, patients with MDs tend to develop worsening contractures and rapidly progressive scoliosis. On average, for each 10° of thoracic scoliosis curvature, the forced vital capacity (FVC) decreases by 4%.[5] In a patient with an already-weakened cardiopulmonary system, this decrease in FVC could rapidly become fatal.

The goal of orthopedic management is, therefore, to preserve or prolong patients' ambulatory status for as long as possible. This goal can be achieved with soft-tissue releases for contractures. If the patient develops significant scoliosis, which generally occurs after they stop walking, early stabilization of the spine should be considered.

Next

Pathophysiology

Multiple proteins are involved in the complex interactions of the muscle membrane and extracellular environment. For sarcolemmal stability, dystrophin and the dystrophin-associated glycoproteins (DAGs) are important elements.[6, 7]

The dystrophin gene is located on the short arm of chromosome X near the p21 locus and codes for the large protein Dp427, which contains 3685 amino acids. Dystrophin accounts for only approximately 0.002% of the proteins in striated muscle, but it has obvious importance in the maintenance of the muscle's membrane integrity.[5]

Dystrophin aggregates as a homotetramer at the costomeres in skeletal muscles, as well as associates with actin at its N-terminus and the DAG complex at the C-terminus, forming a stable complex that interacts with laminin in the extracellular matrix. Lack of dystrophin leads to cellular instability at these links, with progressive leakage of intracellular components; this results in the high levels of creatine phosphokinase (CPK) noted on routine blood workup of patients with Duchenne MD.

Less-active forms of dystrophin may still function as a sarcolemmal anchor, but they may not be as effective a gateway regulator because they allow some leakage of intracellular substance. This is the classic Becker dystrophy. In both Duchenne and Becker MD, the muscle-cell unit gradually dies, and macrophages invade. Although the damage in MD is not reported to be immunologically mediated, class I human leukocyte antigens (HLAs) are found on the membrane of dystrophic muscles; this feature makes these muscles more susceptible to T-cell mediated attacks.

Selective monoclonal antibody hybridization was used to identify cytotoxic T cells as the invading macrophages; complement-activated membrane attack complexes have been identified in dystrophic muscles as well. Over time, the dead muscle shell is replaced by a fibrofatty infiltrate, which clinically appears as pseudohypertrophy of the muscle. The lack of functioning muscle units causes weakness and, eventually, contractures.

Other types of MDs are caused by alterations in the coding of one of the DAG complex proteins. The gene loci coding for each of the DAG complex proteins is located outside the X chromosomes. Gene defects in these protein products also lead to alterations in cellular permeability; however, because of the slightly different mechanism of action and because of the locations of these gene products within the body, there are other associated effects, such as those in ocular and limb-girdle type dystrophies (see the image below).

Schematic of the sarcomere with labeled molecular Schematic of the sarcomere with labeled molecular components that are known to cause limb-girdle muscular dystrophy or myofibrillar myopathy. Mutations in actin and nebulin cause the congenital myopathy nemaline rod myopathy, and the mutations in myosin cause familial hypertrophic cardiomyopathy. Image courtesy of Dr F. Schoeni-Affoher, University of Friberg, Switzerland.
Previous
Next

Etiology

Classification of types of muscular dystrophy

The etiology of MD is an abnormality in the genetic code for specific muscle proteins.[8] They all are classified according to the clinical phenotype, the pathology, and the mode of inheritance. The inheritance pattern includes the sex-linked, autosomal recessive, and autosomal dominant MDs. Within each group of heritable MDs (see below), several disorders exist. These are characterized by the clinical presentation and pathology.

Heritable MDs include the following:

  • Sex-linked MDs - Duchenne, Becker, Emery-Dreifuss
  • Autosomal dominant MDs - Facioscapulohumeral, distal, ocular, oculopharyngeal
  • Autosomal recessive MD – Limb-girdle form

Genetic defects and dystrophin

In the X-linked forms of MD, such as the Duchenne and Becker dystrophies, the defect is located on the short arm of the X chromosome.[9] Hoffman and coworkers identified the locus of the defect in the Xp21 region, which includes approximately 2 million base pairs.[5] The gene codes for Dp427, which is a component of the cytoskeleton of the cell membrane.

Dystrophin is distributed not only in skeletal muscle but also in smooth and cardiac muscles and in the brain. The large size of the dystrophin gene explains the ease at which spontaneous new mutations can occur, as in Duchenne MD. The large size also allows mistakes in protein synthesis to occur at multiple sites.

Defects that interfere with the translation reading frame or with the promoter sequence that initiates synthesis of dystrophin lead to an unstable, ineffective protein, as in Duchenne MD. Disruption of the translation process further down the sequence leads to production of proteins of lower molecular weight that, although present, are less active and result in the milder variety of Becker MD.

Like Duchenne MD, Emery-Dreifuss MD is a sex-linked recessive disorder, but its defect is localized to the long arm of the X chromosome at the q28 locus.[10] Some authors, however, have cited case reports of similar findings in Emery-Dreifuss that were transmitted in an autosomal dominant pattern.[11] However, this finding is more of an aberration than a normal observation in Emery-Dreifuss MD.

In autosomal recessive conditions such as limb-girdle MD, the genetic defect is localized to the 13q12 locus.

In the autosomal dominant facioscapulohumeral MD, the defect is at the 4q35 locus. In distal MD, it is at the 2q12-14 loci.[12]

Previous
Next

Epidemiology

United States statistics

The incidence of MD varies, depending on the specific type of MD under consideration. Duchenne MD is the most common MD and is sex-linked, with an inheritance pattern of 1 case per 3500 live male births.[13, 14] One third of cases occurs as a result of spontaneous new mutations.[15] Becker MD is the second most common form, with an incidence of 1 case per 30,000 live male births.[16] Other types of MD are rare. For example, limb-girdle dystrophy occurs in only 1.3% of patients with MDs.

International statistics

The incidence internationally is similar to that of the US for most of the dystrophies, except for the oculopharyngeal type, which is more common in French Canadians than in other groups.[17] Distal MD tends to occur in Sweden.

Previous
Next

Prognosis

Despite modern advances in gene therapy and molecular biology, MD remains incurable. With proper care and attention, patients have a better quality of life than they would otherwise, but most still die by the time they are age 30 years, usually as a result of cardiopulmonary failure.

Previous
 
 
Contributor Information and Disclosures
Author

Twee T Do, MD Clinical Faculty, Rocky Vista University College of Osteopathic Medicine; Attending Surgeon, Advanced Orthopedics

Twee T Do, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Academy of Pediatrics, Colorado Medical Society, Scoliosis Research Society, Pediatric Orthopaedic Society of North America

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

George H Thompson, MD Director of Pediatric Orthopedic Surgery, Rainbow Babies and Children’s Hospital, University Hospitals Case Medical Center, and MetroHealth Medical Center; Professor of Orthopedic Surgery and Pediatrics, Case Western Reserve University School of Medicine

George H Thompson, MD is a member of the following medical societies: American Orthopaedic Association, Scoliosis Research Society, Pediatric Orthopaedic Society of North America, American Academy of Orthopaedic Surgeons

Disclosure: Received none from OrthoPediatrics for consulting; Received salary from Journal of Pediatric Orthopaedics for management position; Received none from SpineForm for consulting; Received none from SICOT for board membership.

Chief Editor

Jeffrey D Thomson, MD Associate Professor, Department of Orthopedic Surgery, University of Connecticut School of Medicine; Director of Orthopedic Surgery, Department of Pediatric Orthopedic Surgery, Associate Director of Clinical Affairs for the Department of Surgical Subspecialties, Connecticut Children’s Medical Center; President, Connecticut Children's Specialty Group

Jeffrey D Thomson, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons

Disclosure: Nothing to disclose.

Additional Contributors

Charles T Mehlman, DO, MPH Professor of Pediatrics and Pediatric Orthopedic Surgery, Division of Pediatric Orthopedic Surgery, Director, Musculoskeletal Outcomes Research, Cincinnati Children's Hospital Medical Center

Charles T Mehlman, DO, MPH is a member of the following medical societies: American Academy of Pediatrics, American Fracture Association, Scoliosis Research Society, Pediatric Orthopaedic Society of North America, American Medical Association, American Orthopaedic Foot and Ankle Society, American Osteopathic Association, Arthroscopy Association of North America, North American Spine Society, Ohio State Medical Association

Disclosure: Nothing to disclose.

References
  1. Conte G, Gioja L. Scrofola del sistema muscolare. Annali Clinici dell'Ospedale degli Incurabili di Napoli. 1836. 2:66-79.

  2. Meryon E. On granular and fatty degeneration of the voluntary muscles. Medico-Chirurgical Trans. 1852. 35:73-4.

  3. Duchenne GBA. Recherches sur la paralysie musculaire pseudo-hypertrophique ou paralysie myo-sclerosique. Arch Gen Med. 1868. 11:5-25.

  4. Yanagisawa A, Bouchet C, Quijano-Roy S, Vuillaumier-Barrot S, Clarke N, Odent S, et al. POMT2 intragenic deletions and splicing abnormalities causing congenital muscular dystrophy with mental retardation. Eur J Med Genet. 2008 Dec 27. [Medline].

  5. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987 Dec 24. 51(6):919-28. [Medline].

  6. Waite A, Tinsley CL, Locke M, Blake DJ. The neurobiology of the dystrophin-associated glycoprotein complex. Ann Med. 2009 Jan 26. 1-16. [Medline].

  7. Banks GB, Chamberlain JS, Froehner SC. Truncated dystrophins can influence neuromuscular synapse structure. Mol Cell Neurosci. 2009 Jan 8. [Medline].

  8. Bushby K. Genetics and the muscular dystrophies. Dev Med Child Neurol. 2000 Nov. 42(11):780-4. [Medline].

  9. González-Herrera L, Gamas-Trujillo PA, García-Escalante MG, Castillo-Zapata I, Pinto-Escalante D. [Identifying deletions in the dystrophin gene and detecting carriers in families with Duchenne's/Becker's muscular dystrophy]. Rev Neurol. 2009 Jan 16-31. 48(2):66-70. [Medline].

  10. Dickey RP, Ziter FA, Smith RA. Emery-Dreifuss muscular dystrophy. J Pediatr. 1984 Apr. 104(4):555-9. [Medline].

  11. Miller RG, Layzer RB, Mellenthin MA, et al. Emery-Dreifuss muscular dystrophy with autosomal dominant transmission. Neurology. 1985 Aug. 35(8):1230-3. [Medline].

  12. Dobrowski JM, Zajtchuk JT, LaPiana FG, Hensley SD Jr. Oculopharyngeal muscular dystrophy: clinical and histopathologic correlations. Otolaryngol Head Neck Surg. 1986 Sep. 95(2):131-42. [Medline].

  13. Dubowitz V. Muscle Disorders in Childhood. 2nd ed. Philadelphia, Pa: WB Saunders. 1995: 34-132.

  14. Emery AE. Duchenne's muscular dystrophy. In: Oxford Monographs on Medical Genetics Series #24. 2nd ed. Oxford, United Kingdom: Oxford University Press;. 1993.

  15. Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord. 1991. 1(1):19-29. [Medline].

  16. Shapiro F, Specht L. The diagnosis and orthopaedic treatment of inherited muscular diseases of childhood. J Bone Joint Surg Am. 1993 Mar. 75(3):439-54. [Medline].

  17. Pratt MF, Meyers PK. Oculopharyngeal muscular dystrophy: recent ultrastructural evidence for mitochondrial abnormalities. Laryngoscope. 1986 Apr. 96(4):368-73. [Medline].

  18. Donders J, Taneja C. Neurobehavioral Characteristics of Children with Duchenne Muscular Dystrophy. Child Neuropsychol. 2009 Jan 22. 1-10. [Medline].

  19. Prosser EJ, Murphy EG, Thompson MW. Intelligence and the gene for Duchenne muscular dystrophy. Arch Dis Child. 1969 Apr. 44(234):221-30. [Medline].

  20. Leibowitz D, Dubowitz V. Intellect and behaviour in Duchenne muscular dystrophy. Dev Med Child Neurol. 1981 Oct. 23(5):577-90. [Medline].

  21. Pane M, Lombardo ME, Alfieri P, D'Amico A, Bianco F, Vasco G, et al. Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation. J Pediatr. 2012 May 4. [Medline].

  22. Thompson GH, Berenson FR. Other neuromuscular disorders. In: Morrissy RT, Weinstein SL, Winter RB, eds. Lovell and Winter's Pediatric Orthopaedics. 5th ed. Lippincott Williams & Wilkins;. 2000: 540-51.

  23. Sussman MD. Advantage of early spinal stabilization and fusion in patients with Duchenne muscular dystrophy. J Pediatr Orthop. 1984 Sep. 4(5):532-7. [Medline].

  24. Weimann RL, Gibson DA, Moseley CF. Surgical stabilization of the spine in Duchenne muscular dystrophy. Spine. 1983 Oct. 8(7):776-80. [Medline].

  25. Almenrader N, Patel D. Spinal fusion surgery in children with non-idiopathic scoliosis: is there a need for routine postoperative ventilation?. Br J Anaesth. 2006 Dec. 97(6):851-7. [Medline].

  26. Kinali M, Messina S, Mercuri E, et al. Management of scoliosis in Duchenne muscular dystrophy: a large 10-year retrospective study. Dev Med Child Neurol. 2006 Jun. 48(6):513-8. [Medline].

  27. Birnkrant DJ. New challenges in the management of prolonged survivors of pediatric neuromuscular diseases: a pulmonologist's perspective. Pediatr Pulmonol. 2006 Dec. 41(12):1113-7. [Full Text].

  28. Miller RG, Chalmers AC, Dao H, et al. The effect of spine fusion on respiratory function in Duchenne muscular dystrophy. Neurology. 1991 Jan. 41(1):38-40. [Medline].

  29. Miller F, Moseley CF, Koreska J, Levison H. Pulmonary function and scoliosis in Duchenne dystrophy. J Pediatr Orthop. 1988 Mar-Apr. 8(2):133-7. [Medline].

  30. Thrush PT, Allen HD, Viollet L, Mendell JR. Re-examination of the electrocardiogram in boys with Duchenne muscular dystrophy and correlation with its dilated cardiomyopathy. Am J Cardiol. 2009 Jan 15. 103(2):262-5. [Medline].

  31. Chamberlain JS, Gibbs RA, Ranier JE. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 1988 Dec 9. 16(23):11141-56. [Medline]. [Full Text].

  32. Miyazaki D, Yoshida K, Fukushima K, Nakamura A, Suzuki K, Sato T, et al. Characterization of deletion breakpoints in patients with dystrophinopathy carrying a deletion of exons 45-55 of the Duchenne muscular dystrophy (DMD) gene. J Hum Genet. 2009 Jan 9. [Medline].

  33. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 1974 Dec 14. 2(7894):1409-12. [Medline].

  34. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989 Jun 15. 320(24):1592-7. [Medline].

  35. McAdam LC, Mayo AL, Alman BA, Biggar WD. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myol. 2012 May. 31 (1):16-20. [Medline].

  36. Lebel DE, Corston JA, McAdam LC, Biggar WD, Alman BA. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am. 2013 Jun 19. 95 (12):1057-61. [Medline].

  37. Casey A, Constantin-Teodosiu D, Howell S, Hultman E, Greenhaff PL. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am J Physiol. 1996 Jul. 271(1 Pt 1):E31-7. [Medline].

  38. Tarnopolsky MA, MacLennan DP. Creatine monohydrate supplementation enhances high-intensity exercise performance in males and females. Int J Sport Nutr Exerc Metab. 2000 Dec. 10(4):452-63. [Medline].

  39. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve. 1997 Dec. 20(12):1502-9. [Medline].

  40. Chung YL, Alexanderson H, Pipitone N, Morrison C, Dastmalchi M, Ståhl-Hallengren C, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007 May 15. 57(4):694-702. [Medline].

  41. Klopstock T, Querner V, Schmidt F, Gekeler F, Walter M, Hartard M, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology. 2000 Dec 12. 55(11):1748-51. [Medline].

  42. Louis M, Lebacq J, Poortmans JR, Belpaire-Dethiou MC, Devogelaer JP, Van Hecke P, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve. 2003 May. 27(5):604-10. [Medline].

  43. Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev. 2011 Feb 16. 2:CD004760. [Medline].

  44. Hamed SA. Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs. 2006 Nov. 9(11):783-9. [Medline].

  45. PTC Therapeutics, Inc. PTC124 FAQs: frequently asked questions about PTC124. Available at: http://www.ptcbio.com/2.4_faqs.aspx. Accessed: March 19, 2007. [Full Text].

  46. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011 Aug 13. 378(9791):595-605. [Medline].

  47. Ragot T, Vincent N, Chafey P, et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature. 1993 Feb 18. 361(6413):647-50. [Medline].

  48. Wang Z, Allen JM, Riddell SR. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther. 2007 Jan. 18(1):18-26. [Medline].

  49. Howell J, Lochmuller H, O'Hara A. High level dystrophin expression with adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppresion. Hum Gene Ther. 1998 Mar 20. 9(5):629-34. [Medline].

  50. Griggs RC, Karparti G, eds. Myoblast Transfer Therapy (Advances in Experimental Medicine and Biology). Dordrecht, The Netherlands: Kluwer Academic Publishers;. 1990.

  51. Rando TA. Non-viral gene therapy for Duchenne muscular dystrophy: Progress and challenges. Biochim Biophys Acta. 2007 Feb. 1772(2):263-71. [Medline].

  52. Wells DJ. Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy. J Muscle Res Cell Motil. 2006. 27(5-7):387-98. [Medline].

  53. Judge LM, Chamberlain JS. Gene therapy for Duchenne muscular dystrophy: AAV leads the way. Acta Myol. 2005 Dec. 24(3):184-93. [Medline].

  54. Gurpur PB, Liu J, Burkin DJ, Kaufman SJ. Valproic Acid Activates the PI3K/Akt/mTOR Pathway in Muscle and Ameliorates Pathology in a Mouse Model of Duchenne Muscular Dystrophy. Am J Pathol. 2009 Jan 29. [Medline].

  55. Brooke MH, Fenichel GM, Griggs RC, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology. 1989 Apr. 39(4):475-81. [Medline].

  56. Heckmatt JZ, Dubowitz V, Hyde SA, et al. Prolongation of walking in Duchenne muscular dystrophy with lightweight orthoses: review of 57 cases. Dev Med Child Neurol. 1985 Apr. 27(2):149-54. [Medline].

  57. Drennan J. Neuromuscular disorders. In: Lowell WW, Morrissy RT, Winter RB, eds. Lovell and Winter's Pediatric Orthopaedics. 3rd ed. Philadelphia, Pa:. Lippincott Williams & Wilkins. 1990:381.

  58. Yount CC. The role of tensor fascia femoris in certain deformities of the lower extremities. J Bone Joint Surg. 1926. 8:171-93.

  59. Suk KS, Lee BH, Lee HM, Moon SH, Choi YC, Shin DE, et al. Functional outcomes in Duchenne muscular dystrophy scoliosis: comparison of the differences between surgical and nonsurgical treatment. J Bone Joint Surg Am. 2014 Mar 5. 96 (5):409-15. [Medline].

  60. Brooks JT, Sponseller PD. What's New in the Management of Neuromuscular Scoliosis. J Pediatr Orthop. 2015 Apr 13. [Medline].

  61. Jain A, Hassanzadeh H, Strike SA, Menga EN, Sponseller PD, Kebaish KM. Pelvic Fixation in Adult and Pediatric Spine Surgery: Historical Perspective, Indications, and Techniques: AAOS Exhibit Selection. J Bone Joint Surg Am. 2015 Sep 16. 97 (18):1521-8. [Medline].

  62. Gaine WJ, Lim J, Stephenson W. Progression of scoliosis after spinal fusion in Duchenne's muscular dystrophy. J Bone Joint Surg Br. 2004 May. 86(4):550-5. [Medline].

  63. Sengupta DK, Mehdian SH, McConnel JR. Pelvic or lumbar fixation for the surgical management of scoliosis in Duchenne muscular dystrophy. Spine. 2002 Sep 15. 27(18):2072-9. [Medline].

  64. Mubarak SJ, Morin WD, Leach J. Spinal fusion in Duchenne muscular dystrophy-fixation and fusion to the sacropelvis?. J Pediatr Orthop. 1993 Nov-Dec. 13(6):752-7. [Medline].

 
Previous
Next
 
Schematic of the sarcomere with labeled molecular components that are known to cause limb-girdle muscular dystrophy or myofibrillar myopathy. Mutations in actin and nebulin cause the congenital myopathy nemaline rod myopathy, and the mutations in myosin cause familial hypertrophic cardiomyopathy. Image courtesy of Dr F. Schoeni-Affoher, University of Friberg, Switzerland.
Gomori trichrome–stained section in patient with myofibrillar myopathy. Note the abnormal accumulations of blue-red material in several muscle fibers.
Left: The photomicrograph is a muscle biopsy with normal emerin immunostaining. Right: The micrograph is from a patient with X-linked Emery-Dreifuss muscular dystrophy. Note the absence of nuclear staining as well as the hypertrophied and atrophied muscle fibers.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.